Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
about
Targeting the Pim kinases in multiple myelomaHypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.PARP-1 and YY1 are important novel regulators of CXCL12 gene transcription in rat pancreatic beta cellsThe left-right Pitx2 pathway drives organ-specific arterial and lymphatic development in the intestine.SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II.Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1Multiple myeloma in the marrow: pathogenesis and treatments.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Biological aspects of angiogenesis in multiple myeloma.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact.Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response.Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer.Integration of hypoxic HIF-α signaling in blood cancers.A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.Potential targeting of B7-H4 for the treatment of cancer.Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion.Cell Trafficking in Multiple MyelomaNeoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.Novel drugs for the treatment of multiple myelomaHypoxia favors the generation of human plasma cells.Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.Transient HIF2A inhibition promotes satellite cell proliferation and muscle regeneration.
P2860
Q26799499-EE56923C-968D-480B-A9AC-5CC9393F6F0CQ31118586-74AC3000-9E03-4275-BB5A-756BEAB16B19Q33917555-56EB6832-BEBD-4953-8AC2-2961DCE9F7E9Q34651839-E4740918-7F6E-49E5-9CF4-7F1FE0AEB7A9Q35079365-67EBE329-CDBA-4894-BE8E-8435443D0E7DQ35680177-E2D588CA-9EB4-49C9-A532-C418D69076C0Q36057606-C6E50905-85BE-41B9-A8A6-23855AC6F221Q36289608-8C8D36D2-4117-4032-B08B-EF1E4A629709Q36717999-E74D25D9-52BA-499C-A08E-3DB38865B9A7Q36725401-AA28FFF8-CB1B-487A-8D14-CCEFB1719F97Q37884379-35A512C8-449B-492D-874B-CB61DAE437E5Q37956524-C188BDD5-17FD-40A3-818C-2F71B28AA1A3Q38035044-7FE44DD1-8B39-48ED-A2D9-3F356F2BD973Q38056889-B5CCB1C3-2AA1-4907-B8D1-AC7BA277A2ADQ38073136-B60F08FA-C1AF-41AB-AC0F-EF199A6ADD51Q38151195-5A98BAEE-C7C0-41FE-A7EC-818743213BB5Q38472331-FCA2B2CE-620D-4533-891B-6A7B629E2490Q38672565-8D1A47B5-1F5B-4CCF-BAF7-D92EEA6A7D5BQ38697483-23F2228F-42F3-4E79-9406-6027ACA05811Q38724150-54924AE7-2DA7-4E5B-81E7-AF5A20F234A0Q38769432-2B8F9BE4-5C95-4167-977E-FBD142D5E3FEQ38800369-2817ED1A-EA4B-4732-8E42-903AB720F3BCQ38930119-96D475E8-ED99-45D5-B0F3-DA9FB799407EQ39078376-37A7D3CF-BB2B-400F-B1D1-CAC25FC4D2C0Q39285839-D90502DA-4ACF-442A-B3D0-37B9F2FD0AB8Q42146660-712F7148-AC06-4F8E-B7A6-F2C8466EE6BCQ42244787-5C74B22B-78C4-4507-8B7A-5B187F9512CCQ42793018-AFD59CAD-80D0-4FF7-ACE9-EDB8157194A7Q48207902-4AEB5A52-0601-4BCA-93FA-1A4789C446EFQ48955308-80DE5B4D-4B4D-4554-94FB-BAA74C6A098EQ51636063-6364EC76-FC86-4640-AA66-6D0B6F51F119Q52676274-6D7659AD-DC24-4A43-9A5B-7F004C433521Q55286882-6456F7CF-9006-431A-9B35-F1F4D9B2D715
P2860
Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@ast
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@en
type
label
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@ast
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@en
prefLabel
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@ast
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells.
@en
P2093
P2860
P50
P1433
P1476
Hypoxia-inducible factor-2 is ...... multiple myeloma plasma cells
@en
P2093
Luen Bik To
Nobutaka Fujii
Peter Diamond
Sharon A Williams
P2860
P304
P356
10.3324/HAEMATOL.2009.015628
P577
2009-12-16T00:00:00Z